645 related articles for article (PubMed ID: 16485087)
1. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
6. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
8. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
9. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
10. [Transdermal route as an alternative to oral administration of opioids in cancer pain].
Burza M; Ginobbi P; Fusco G; Laurenzi L; Tirelli W; Arcuri E
Clin Ter; 1998; 149(4):277-80. PubMed ID: 9866889
[TBL] [Abstract][Full Text] [Related]
11. Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
Garbe E; Jobski K; Schmid U
Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):191-8. PubMed ID: 21681850
[TBL] [Abstract][Full Text] [Related]
12. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
13. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
Radbruch L; Sabatowski R; Petzke F; Brunsch-Radbruch A; Grond S; Lehmann KA
Palliat Med; 2001 Jul; 15(4):309-21. PubMed ID: 12054148
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
15. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
16. Transdermal opioids for cancer pain.
Skaer TL
Health Qual Life Outcomes; 2006 Mar; 4():24. PubMed ID: 16573839
[TBL] [Abstract][Full Text] [Related]
17. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
Binhas M; Krakowski I; Marty J
Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
[TBL] [Abstract][Full Text] [Related]
18. The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients.
Reddy A; Tayjasanant S; Haider A; Heung Y; Wu J; Liu D; Yennurajalingam S; Reddy S; de la Cruz M; Rodriguez EM; Waletich J; Vidal M; Arthur J; Holmes C; Tallie K; Wong A; Dev R; Williams J; Bruera E
Cancer; 2016 Jan; 122(1):149-56. PubMed ID: 26451687
[TBL] [Abstract][Full Text] [Related]
19. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
20. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
